Standards, options and recommendations for brachytherapy of prostate cancer: Efficacy and toxicity;Standards, options et recommandations pour la curiethérapie des patients atteints de cancer de la prostate: Efficacité et toxicité

Cancer/Radiotherapie

Volumn 5, Issue 6, 2001, Pages 770-786

  Pommier, P ^a,b   Villers, A ^a,b   Bataillard, A ^a,b   Brune, D ^a,b   Fervers, B ^a,b   Bachaud, J M ^a,b   Berger, N ^a,b   Bertrand, A F ^a,b   Bouvier, R ^a,b   Daver, A ^a,b   Fontaine, E ^a,b   Guilloneau, B ^a,b   Haillot, O ^a,b   Lagrange, J L ^a,b   Molinie V ^a,b   Muratet, J P ^a,b   Pabot du Chatelard, P ^a,b   Peneau, M ^a,b   Prapotnitch, D ^a,b   Ravery, V ^a,b   Richaud, P ^a,b   Rossi, D ^a,b   Soret, J Y ^a,b   more..

^a FNCLCC   (France)

^b NONE

Author keywords

Adult; Brachytherapy; Clinical practice guidelines; Efficacy; Prostate cancer; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; HORMONE;

ANTIBIOTIC THERAPY; BEAM THERAPY; BRACHYTHERAPY; CANCER CENTER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; FRANCE; HEALTH CARE QUALITY; HUMAN; INFECTION; MALE; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; REVIEW; STANDARD; TREATMENT OUTCOME;

EID: 0035660455     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1278-3218(01)00138-X     Document Type: Review

References (55)

1. Prostate brachytherapy in patients with prior evidence of prostatitis
2. Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule
3. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer
4. Biochemical disease-free survival following 125I prostate implantation
5. Palladium-103 brachytherapy for prostate carcinoma
6. Urinary morbidity with a modified peripheral loading technique of transperineal (125) I prostate implantation
7. Isotope selection for patients undergoing prostate brachytherapy
8. 125I prostate implant followed by external-beam radiation
9. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
10. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma
11. The radial distance of extraprostatic extension of prostate carcinoma: Implications for prostate brachytherapy
12. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland
13. Méthodologie de développement des standards, options et recommandations diagnostiques et thérapeutiques en cancérologie
14. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation
15. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance
16. 125I brachytherapy
17. Clinical course of rectal bleeding following I-125 prostate brachytherapy
18. Urinary incontinence in patients who have a TURP/TUIP following prostate brachytherapy
19. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: Evidence for a learning curve in the first year at a single institution
20. The relative biological effectiveness of I-125 and Pd-103
21. Rectal dosimetric analysis following prostate brachytherapy
22. Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction
23. Temporal resolution of urinary morbidity following prostate brachytherapy
24. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction
25. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer
26. Pulmonary embolization of permanently implanted radioactive palladium-103 seeds for carcinoma of the prostate
27. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer
28. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis
29. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine-125 interstitial implants
30. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: A 7-year biochemical (PSA) progression analysis
31. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy
32. Potency after permanent prostate brachytherapy for localized prostate cancer
33. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer
34. Brachytherapy for clinically localized prostate cancer: Results at 7- and 8-year follow-up
35. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma
36. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma
37. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up
38. Retrospective comparison of radical retropubic prostatectomy and 125iodine brachytherapy for localized prostate cancer
39. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: A preliminary report of 434 patients
40. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma
41. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer
42. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation
43. Prostate brachytherapy: Treatment strategies
44. Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity
45. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate
46. Radiotherapy options for localized prostate cancer based upon pre-treatment serum prostate-specific antigen levels and biochemical control: A comprehensive review of the literature
47. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy
48. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma
49. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection
50. High dose combination radiotherapy for the treatment of localized prostate cancer
51. Long-term results of retropubic permanent 125 iodine implantation of the prostate for clinically localized prostatic cancer
52. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer
53. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer